Current perspectives of antiamyloid therapy for Alzheimer's Disease
DOI:
https://doi.org/10.34024/rnc.2022.v30.13552Keywords:
Alzheimer Disease, Dementia, Neurodegenerative Diseases, Amyloid beta-Peptides, Immunotherapy, Drug TherapyAbstract
Introduction. According to Alzheimer's Disease International, dementia is a generic term for a set of symptoms caused by disorders that affect the brain and impact memory, thinking, behavior and emotions. The treatment of Alzheimer's disease (AD) is multidisciplinary and should include non-pharmacological and pharmacological therapy. Cholinesterase inhibitors are the drugs of first choice for the treatment of AD, but they have many side effects and do not prevent the progression of the disease. Thus, antiamyloid therapy is a promising alternative in the treatment of AD. Objective. The present study aims to analyze the current perspectives of antiamyloid therapy in the treatment of AD. Method. A survey of scientific articles has been conducted since 2016 in the Databases Scielo, PUBMED, LILACS and BVS. Results. Initially, 109 articles were found in English, Portuguese and German, whose abstracts were read. Conclusions. Based on the analyzed literature, great clinical advances have been made in the face of AD. The future of Alzheimer's treatment probably lies in a multimodal therapeutic approach and the amyloid hypothesis comes as a promising alternative therapy for the treatment of the disease. Thus, we emphasize the importance of promoting discussion and research so that we can get closer and closer to a possible cure and prevention of this condition.
Metrics
References
Fleming R, Zeisel John, Bennett K. World Alzheimer Report 2020. Design Dignity Dementia: dementia-related design and the built environment. Volume 1. London: Alzheimer’s Disease International; 2020. https://www.alzint.org/u/WorldAlzheimerReport2020Vol1.pdf
Falco A, Cukierman DS, Hauser-Davis RA, Rey NA. Doença de Alzheimer: hipóteses etiológicas e perspectivas de tratamento. Quím Nova 2016;39:63-80. https://doi.org/10.5935/0100-4042.20150152
Pinto RS, Rodrigues Neto EM, Barros KBNT, Vasconcelos LMO, Girão Junior FJ, Lobo PLD, et al. Doença de Alzheimer: Abordagem farmacoterapêutica. Bol Info Geum 2015;6:16. https://revistas.ufpi.br/index.php/geum/article/view/3861
Sant’Ana NJ, Garcia Filho PH, Mendonça RR, Kamada M. Terapia antiamiloide: uma nova estratégia para tratamento da doença de Alzheimer. Rev Soc Bras Clín Méd 2018;6:127-31. https://pesquisa.bvsalud.org/portal/resource/pt/biblio-913376
Tolar M, Hey J, Power A, Abushakra S. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. Inter J Mol Sci 2021;22:6355. https://doi.org/10.3390/ijms22126355
Delanogare E, Flores D, Souza RM, Souza L, Gasnhar Moreira EL. Hipótese amiloide e o tratamento da doença de Alzheimer: revisão dos estudos clínicos realizados. VITTALLE Rev Ciênc Saúde 2019;31:84-106. https://doi.org/10.14295/vittalle.v31i1.8395
Lowe SL, Duggan EC, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I, et al. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. J Prevent Alzheimer Dis 2021;8:414-24. https://doi.org/10.14283/jpad.2021.56
Decourt B, Boumelhem F, Pope ED, 3rd Shi J, Mari Z, Sabbagh MN. Critical Appraisal of Amyloid Lowering Agents in AD. Curr Neurol Neurosc Rep 2021;21:39. https://doi.org/10.1007/s11910-021-01125-y
Yu T-W, Lane H-Y, Lin C-H. Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review. Inter J Mol Sci 2021;22:8208. https://doi.org/10.3390/ijms22158208
Jeremic D, Jiménez-Díaz L, Navarro-López JD. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review. Ageing Res Rev 2021;72:101496. https://doi.org/10.1016/j.arr.2021.101496
Frölich L, Hausner L. Disease-modifying treatment approaches for Alzheimer's disease. Der Nervenarzt 2021;92:1239-48. https://doi.org/10.1007/s00115-021-01222-w
Tousi B, Sabbagh MN. A Time of Transition Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies. Neurol Ther 2021;editorial:1-5. https://doi.org/10.1007/s40120-021-00286-9
Weiner MW, Aisen PS, Beckett LA, Green RC, Jagust W, Morris JC, et al. How Will Aducanumab Approval Impact AD Research? J Prevent Alzheimer Dis 2021;8:391-2. https://doi.org/10.14283/jpad.2021.46
Walsh S, Merrick R, Milne R, Brayne C. Aducanumab for Alzheimer's disease? BMJ 2021;374:1682. https://doi.org/10.1136/bmj.n1682
Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimer Dement 2021;7:e12112. https://doi.org/10.1002/trc2.12112
Esang M, Gupta M. Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controversies, and the Future. Cureus 2021;13:e17591. https://doi.org/10.7759/cureus.17591
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s disease. New Eng J Med 2021;384:1691-704. https://doi.org/10.1056/NEJMoa2100708
Pais M, Martinez L, Ribeiro O, Loureiro J, Fernandez R, Valiengo L, et al. Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges. Braz J Psychiatr 2020;42:431-41. https://doi.org/10.1590/1516-4446-2019-0735
Santana ACF, Magalhães GJP. Resveratrol in Alzheimer's disease: a review of pathophysiology and therapeutic potential. Arq Neuropsiqu 2020;78:501-11. https://doi.org/10.1590/0004-282X20200010
Kozin SA, Barykin EP, Mitkevich VA, Makarov AA. Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects. Biochem Moscow 2018;83:1057-067. https://doi.org/10.1134/s0006297918090079
Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep 2018;8:1-16. https://doi.org/10.1038/s41598-018-24501-0
van Dyck CH. Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol Psychiatr 2018;83:311-9. https://doi.org/10.1016/j.biopsych.2017.08.010
Ginestal-López RC. Immunotherapy for neurological diseases, present and future. Farm Hosp 2018;42:251-60. https://dx.doi.org/10.7399/fh.11031
Cazarim MDS, Moriguti JC, Ogunjimi AT, Pereira LRL. Perspectives for treating Alzheimer's disease: a review on promising pharmacological substances. SPMJ 2016;134:342-54. https://doi.org/10.1590/1516-3180.2015.01980112
Imbimbo BP, Watling M. Inibidores BACE investigacionais para o tratamento da doença de Alzheimer. Opin Investig Drugs 2019;28:967-75. https://doi.org/10.1080/13543784.2019.1683160
Toledo RG, Patricio BMK, Verde LDALV, Martin RRH, Gontijo BDAV, Souza Guimarães J, et al. Anticorpos monoclonais anti-βeta-amilóide no tratamento da doença de Alzheimer: uma revisão sistemática. Braz J Health Ver 2020;3:18990-9. https://doi.org/10.34119/bjhrv3n6-284
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Ana Maria Santos Cardoso, Lucas Mainardo Rodrigues Bezerra, Cynthia Cardozo Lima, Isadora Maria Rodrigues Bezerra, José Lopes Pereira Júnior, João Gustavo Porto Torres
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
Accepted 2022-06-23
Published 2022-08-16
